,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,485,1,8,,26719833,65999,Inactive,38788193.0,1903.0,,,Primary HTS Assay for S1P3 Antagonists,Screening,,
1,631,1,4,,26719833,65999,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
2,631,1,4,,26719833,65999,Inactive,22538455.0,8648.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
3,731,1,5,,26719833,65999,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
4,731,1,5,,26719833,65999,Inactive,32307126.0,8202.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
5,781,1,1,,26719833,65999,Inactive,27807367.0,287022.0,,,uHTS for 14-3-3/Bad interaction inhibitors,Screening,,
6,782,1,2,,26719833,65999,Inactive,83627717.0,13684.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
7,782,1,2,,26719833,65999,Inactive,302699239.0,1981.0,,,uHTS for Small Molecule Inhibitors of Eukaryotic Translation Initiation,Screening,,
8,875,1,2,,26749005,65999,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
9,880,2,1,,26719833,65999,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
10,880,2,1,,26719833,65999,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
11,880,2,1,,26749005,65999,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
12,880,2,1,,26749005,65999,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
13,881,2,2,,26749005,65999,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
14,884,1,2,,26749005,65999,Inconclusive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
15,885,1,2,,26749005,65999,Inactive,13435386.0,1576.0,15.8489,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
16,887,1,2,,26749005,65999,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
17,889,1,3,,26749005,65999,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
18,892,1,2,,26749005,65999,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
19,893,1,2,,26749005,65999,Active,122921310.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
20,893,1,2,,26749005,65999,Active,122921311.0,,31.6228,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
21,894,2,1,,26749005,65999,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
22,900,1,3,,26749005,65999,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
23,902,1,2,,26749005,65999,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
24,910,1,2,,26749005,65999,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
25,923,1,2,,26749005,65999,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
26,924,1,2,,26749005,65999,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
27,927,1,3,,26749005,65999,Inactive,188528692.0,9099.0,10.0,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
28,930,1,2,,26749005,65999,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
29,940,1,2,,26612858,65999,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
30,950,1,1,,26719833,65999,Inactive,231632.0,596.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-2.",Screening,,
31,951,1,1,,26719833,65999,Inactive,23396469.0,10017.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-B.",Screening,,
32,952,1,1,,26719833,65999,Inactive,1572493.0,599.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-W.",Screening,,
33,995,1,2,,26749005,65999,Inconclusive,66932916.0,5594.0,15.8489,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
34,1001,2,2,,26719833,65999,Inactive,116734717.0,249.0,,EC50,uHTS identification of compounds activating TNAP in the absence of phosphate acceptor performed in luminescent assay,Confirmatory,,
35,1006,1,6,,26719833,65999,Inactive,,,,,Counter Screen for Luciferase-based Primary Inhibition Assays,Screening,,
36,1007,1,1,,26719833,65999,Inactive,510901.0,598.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bcl-XL.",Screening,,
37,1008,1,2,,26719833,65999,Inactive,4757840.0,597.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1",Screening,,
38,1009,1,2,,26719833,65999,Inactive,7582271.0,4170.0,,,"Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Mcl-1",Screening,,
39,1012,1,4,,26719833,65999,Inactive,116734717.0,249.0,,,uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay,Screening,,
40,1016,1,4,,26719833,65999,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase,Screening,,
41,1018,2,5,,26719833,65999,Inactive,8744934.0,,,IC50,Chemical Antagonists IAP-family anti-apoptotic proteins,Confirmatory,,
42,1019,1,4,,26719833,65999,Inactive,68299797.0,280993.0,,,Luminescent assay for identification of inhibitors of bovine intestinal alkaline phosphatase,Screening,,
43,1020,1,5,,26719833,65999,Inactive,149631.0,,,,Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay,Screening,,
44,1021,1,1,,26719833,65999,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Bid interaction inhibitors,Screening,,
45,1022,1,1,,26719833,65999,Inactive,7582271.0,4170.0,,,uHTS of Mcl-1/Noxa interaction inhibitors,Screening,,
46,1027,1,3,,26719833,65999,Inactive,,,,,Counter Screen for Luciferase-based Primary Stimulation Assays,Screening,,
47,1030,2,1,,26749005,65999,Inconclusive,30582681.0,216.0,39.8107,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
48,1032,1,2,,26719833,65999,Inactive,20336229.0,5468.0,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
49,1032,1,2,,26719833,65999,Inactive,62201602.0,,,,Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Screening,,
50,1040,1,2,,26719833,65999,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for antagonists of NPY-Y1,Screening,,
51,1048,1,1,,26719833,65999,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
52,1048,1,1,,26719833,65999,Inactive,32307126.0,8202.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
53,1049,1,1,,26719833,65999,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
54,1049,1,1,,26719833,65999,Inactive,62201602.0,,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
55,1051,1,1,,26719833,65999,Inactive,20336229.0,5468.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
56,1051,1,1,,26719833,65999,Inactive,22538455.0,8648.0,,,Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma),Other,,
57,1066,1,2,,26719833,65999,Inactive,9937384.0,,,,High Throughput Screen to Identify Compounds that Inhibit Class II HMG-CoA Reductases  - Primary Screen,Screening,,
58,1085,1,1,,26719833,65999,Inactive,139424501.0,5176170.0,,,uHTS for Small Molecule Inhibitiors of Epstein-Barr Virus Inhibitors,Screening,,
59,1135,1,3,,26719833,65999,Inactive,116734717.0,249.0,,,uHTS identification of compounds inhibiting TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
60,1136,1,3,,26719833,65999,Inactive,116734717.0,249.0,,,uHTS identification of compounds activating TNAP at a high concentration of phosphate acceptor detected in a luminescent assay,Screening,,
61,1195,1,2,,48416595,65999,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
62,1203,1,3,,26719833,65999,Inactive,12803275.0,3303.0,,,Primary cell-based high-throughput screening assay to identify transcriptional activators of heat shock protein 70 (Hsp70),Screening,,
63,1209,2,2,,26719833,65999,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Confirmatory,,
64,1214,1,4,,26719833,65999,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay.,Screening,,
65,1216,1,5,,26719833,65999,Inactive,16878311.0,4351.0,,,HTS identification of compounds activating phosphomannose isomerase (PMI) via a fluorescence intensity assay using a near- saturating concentration of mannose 6-phosphat,Screening,,
66,1217,1,4,,26719833,65999,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
67,1220,2,2,,26719833,65999,Inactive,16878311.0,4351.0,,IC50,HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate,Confirmatory,,
68,1222,1,6,,26719833,65999,Inactive,,,,EC50,High Throughput Screen for Inhibitors of ER Stress-induced Cell Death in a 384 well format.,Confirmatory,,
69,1229,1,3,,26719833,65999,Inactive,17391426.0,1738.0,,,uHTS Identification of Diaphorase Activators and Chemical Reducers: Counter Screen for Diaphorase-based Primary Assays,Screening,,
70,1236,1,1,,26719833,65999,Inactive,1628587.0,397393.0,,,uHTS for Calpain Inhibitors,Screening,,
71,1251,1,1,,26719833,65999,Inactive,,,,,"Anti-Viral Drugs Against Arbovirus Infections, a Primary Screen",Screening,,
72,1274,1,2,,26719833,65999,Inactive,115298672.0,653361.0,,,"uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)",Screening,,
73,1304,1,2,,26719833,65999,Inactive,4505445.0,4886.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y1,Screening,,
74,1321,1,2,,26719833,65999,Inactive,47123300.0,7465.0,,,Primary Cell-based High Throughput Screening Assay for Inhibitors of Wee1 Degradation,Screening,,
75,1325,1,2,,26719833,65999,Inactive,62526033.0,9429.0,,,"High-throughput multiplex screening for ABC transporter inhibitors: specifically ABCG2 screen, ABCB1 counter-screen",Screening,,
76,1359,1,4,,26719833,65999,Inactive,4505447.0,4887.0,,,Primary cell-based high-throughput screening assay for potentiators or agonists of NPY-Y2,Screening,,
77,1362,1,2,,26719833,65999,Inactive,,,,,Chemical Genetic Screen to Identify Inhibitors of Mitochondrial Fusion - Primary Screen,Screening,,
78,1376,1,2,,49648460,65999,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
79,1379,1,2,,26749005,65999,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
80,1385,2,2,,49648460,65999,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
81,1415,1,2,,26719833,65999,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
82,1415,1,2,,26719833,65999,Inactive,86301151.0,5999.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.",Screening,,
83,1416,1,2,,26719833,65999,Inactive,134304838.0,9451.0,,,Primary cell-based high-throughput screening assay to measure PERK inhibition,Screening,,
84,1422,1,1,,26612858,65999,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
85,1422,1,1,,49648460,65999,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
86,1423,1,2,,26719833,65999,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
87,1423,1,2,,26719833,65999,Inactive,74355113.0,85397.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.",Screening,,
88,1424,1,1,,26719833,65999,Inactive,34330186.0,368273.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel N1 (TRPN1),Screening,,
89,1434,2,3,,26719833,65999,Inactive,13124881.0,865.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
90,1434,2,3,,26719833,65999,Inactive,19923198.0,861.0,,IC50,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.,Confirmatory,,
91,1439,1,1,,26719833,65999,Inactive,1166512.0,6000.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
92,1439,1,1,,26719833,65999,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.",Screening,,
93,1440,1,1,,26719833,65999,Inconclusive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
94,1440,1,1,,26719833,65999,Inconclusive,86990435.0,10287.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS19-Galphao.",Screening,,
95,1441,1,1,,26719833,65999,Inactive,10567816.0,2775.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
96,1441,1,1,,26719833,65999,Inactive,156416009.0,6004.0,,,"Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS16-Galphao.",Screening,,
97,1443,1,3,,26719833,65999,Inactive,4507593.0,8743.0,,,uHTS for the identification of compounds that potentiate TRAIL-induced apoptosis of cancer cells,Screening,,
98,1445,1,1,,26719833,65999,Inactive,124512980.0,813945.0,,IC50,Inhibitors of Plasmodium falciparum M1- Family Alanyl Aminopeptidase (M1AAP),Confirmatory,,
99,1446,1,3,,26719833,65999,Inactive,119579178.0,3717.0,,,Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F,Screening,,
100,1448,1,3,,26719833,65999,Inactive,38174238.0,55283.0,,,Primary cell-based high-throughput screening assay to identify agonists of the transient receptor potential channel ML3 (TRPML3),Screening,,
101,1452,1,1,,26749005,65999,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
102,1454,1,1,,26719833,65999,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
103,1454,1,1,,26749005,65999,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
104,1456,1,1,,26719833,65999,Active,12003227.0,57468.0,,,Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Screen,Other,,
105,1457,1,1,,26749005,65999,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
106,1458,1,1,,26749005,65999,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
107,1460,1,3,,26719833,65999,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
108,1460,1,3,,26749005,65999,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
109,1461,1,2,,26719833,65999,Active,46395496.0,387129.0,1.2589,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
110,1463,1,1,,26719833,65999,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
111,1463,1,1,,26749005,65999,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
112,1465,1,1,,49648460,65999,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
113,1466,1,2,,26719833,65999,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
114,1467,1,3,,26719833,65999,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
115,1467,1,3,,26749005,65999,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
116,1468,1,1,,26719833,65999,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
117,1468,1,1,,26749005,65999,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
118,1469,1,1,,26719833,65999,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
119,1469,1,1,,26749005,65999,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
120,1471,2,1,,26749005,65999,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
121,1476,2,1,,26749005,65999,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
122,1477,1,1,,26719833,65999,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
123,1477,1,1,,26749005,65999,Inconclusive,,,6.3096,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
124,1478,2,1,,26749005,65999,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
125,1479,1,2,,26719833,65999,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
126,1479,1,2,,26749005,65999,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
127,1481,1,2,,26719833,65999,Inactive,111305821.0,7415.0,,,Primary biochemical high-throughput screening assay to measure P97 ATPase inhibition,Screening,,
128,1486,1,3,,26719833,65999,Inactive,,,,,Counterscreen for inhibitors of Janus kinase 2 mutant JAK2V617F: Cell-based high throughput assay to identify inhibitors of parental Ba/F3 cell viability.,Screening,,
129,1487,1,1,,26719833,65999,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
130,1487,1,1,,26749005,65999,Inconclusive,27436948.0,4000.0,0.0008,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
131,1490,2,1,,26719833,65999,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
132,1490,2,1,,26749005,65999,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
133,1496,1,4,,26719833,65999,Inactive,13124881.0,865.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
134,1496,1,4,,26719833,65999,Inactive,19923198.0,861.0,,,uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.,Screening,,
135,1509,1,2,,26719833,65999,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
136,1510,1,3,,26719833,65999,Inactive,15929025.0,8698.0,,,Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4),Screening,,
137,1511,1,3,,49648460,65999,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
138,1515,1,2,,26719833,65999,Inactive,24119166.0,10741.0,,,Primary biochemical high throughput screening assay to identify inhibitors of Retinoblastoma binding protein 9 (RBBP9),Screening,,
139,1519,1,3,,26749005,65999,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
140,1527,1,3,,26719833,65999,Inactive,7381449.0,14678525.0,,,Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase,Screening,,
141,1529,1,1,,26719833,65999,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
142,1529,1,1,,49648460,65999,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
143,1530,1,1,,26719833,65999,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
144,1530,1,1,,49648460,65999,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
145,1531,1,1,,26719833,65999,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
146,1531,1,1,,49648460,65999,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
147,1532,1,1,,49648460,65999,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
148,1533,1,1,,26719833,65999,Inactive,15610402.0,888704.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
149,1533,1,1,,26719833,65999,Inactive,15610601.0,887352.0,,,Rml C and D inhibition 384-well mixture HTS from 1536-well compound plates,Screening,,
150,1554,1,1,,49648460,65999,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
151,1556,1,4,,26719833,65999,Inactive,27368096.0,,,,Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of IMP-1 metallo-beta-lactamase,Screening,,
152,1565,2,2,,26719833,65999,Inactive,219689097.0,162466.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit PHOSPHO1,Confirmatory,,
153,1566,2,3,,26719833,65999,Inactive,11545912.0,64127.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD2,Confirmatory,,
154,1578,3,2,,26719833,65999,Inactive,5174617.0,10392.0,,EC50,uHTS luminescence assay for the identification of compounds that inhibit NOD1,Confirmatory,,
155,1619,1,2,,26719833,65999,Inactive,124809582.0,812021.0,,IC50,Inhibitors of Plasmodium falciparum M17- Family Leucine Aminopeptidase (M17LAP),Confirmatory,,
156,1621,1,2,,49648460,65999,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
157,1625,2,2,,26719833,65999,Inactive,,,,EC50,HCS for Compounds that Up-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
158,1626,1,2,,26719833,65999,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
159,1626,1,2,,49648460,65999,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
160,1628,2,2,,26719833,65999,Inactive,,,,IC50,HCS for Compounds that Down-Regulate Insulin Promoter Activity in MIN6 Cells,Confirmatory,,
161,1631,3,1,,26719833,65999,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
162,1634,3,1,,26719833,65999,Inactive,33286418.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle isoform 2 Pyruvate Kinase,Confirmatory,,
163,1654,2,2,,26719833,65999,Inactive,4758208.0,1845.0,,IC50,uHTS absorbance assay for the identification of compounds that inhibit VHR1.,Confirmatory,,
164,1656,2,2,,26719833,65999,Inactive,,,,,High Throughput Imaging Assay for Hepatic Lipid Droplet Formation,Screening,,
165,1662,1,2,,49648460,65999,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
166,1663,1,2,,49648460,65999,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
167,1665,2,2,,26719833,65999,Inactive,4503131.0,1499.0,,IC50_Mean,High Throughput Imaging Assay for Beta-Catenin,Confirmatory,,
168,1672,1,3,,49648460,65999,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
169,1688,1,1,,26749005,65999,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
170,1700,1,2,,26719833,65999,Inactive,124263658.0,688.0,,,Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5),Screening,,
171,1706,1,2,,26719833,65999,Inactive,73745819.0,,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the SARS coronavirus 3C-like Protease (3CLPro),Screening,,
172,1721,1,2,,26719833,65999,Inactive,290753097.0,,,Potency,qHTS Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
173,1722,1,2,,26719833,65999,Inactive,290753097.0,,,Potency,qHTS Assay for Activators of Leishmania Mexicana Pyruvate Kinase (LmPK),Confirmatory,,
174,1766,1,1,,26719833,65999,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
175,1766,1,1,,26719833,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
176,1766,1,1,,26749005,65999,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
177,1766,1,1,,26749005,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
178,1768,1,1,,26719833,65999,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
179,1768,1,1,,26719833,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
180,1768,1,1,,26749005,65999,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
181,1768,1,1,,26749005,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
182,1775,1,2,,26719833,65999,Inactive,,,,,Profiling compound fluorescence on Avidin Beads with 488 nm excitation and 530 nm emission,Other,,
183,1776,1,2,,26719833,65999,Inactive,,,,,Profiling compound fluorescence on GSH Beads with 488 nm excitation and 530 nm emission,Other,,
184,1777,3,2,,26719833,65999,Inactive,39725940.0,4986.0,,EC50,uHTS identification of small molecule agonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
185,1778,3,3,,26719833,65999,Inactive,39725940.0,4986.0,,IC50,uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay,Confirmatory,,
186,1779,2,2,,26719833,65999,Inactive,224586929.0,26191.0,,IC50,uHTS identification of small molecule inhibitors of LYP via a fluorescence intensity assay,Confirmatory,,
187,1789,1,2,,26719833,65999,Inactive,83318444.0,3320.0,,,Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90),Screening,,
188,1800,1,2,,26719833,65999,Inactive,125541954.0,,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3),Screening,,
189,1813,1,2,,49648460,65999,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
190,1814,1,2,,49648460,65999,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
191,1817,2,2,,26719833,65999,Inactive,40849930.0,5339.0,,IC50,uHTS identification of small molecule antagonists of the binding of Siah-1 and a peptide ligand via a fluorescence polarization assay.,Confirmatory,,
192,1822,1,3,,26719833,65999,Inactive,23505220.0,813594.0,,,QFRET-based primary biochemical high throughput screening assay to identify inhibitors of the Plasmodium falciparum M18 Aspartyl Aminopeptidase (PFM18AAP).,Screening,,
193,1825,1,1,,26719833,65999,Inactive,,,,,Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.,Screening,,
194,1832,2,1,,49648460,65999,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
195,1845,1,2,,26719833,65999,Inactive,125541954.0,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID),Screening,,
196,1850,2,1,,49648460,65999,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
197,1861,2,1,,26719833,65999,Inactive,119607128.0,2831.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7).,Screening,,
198,1863,2,1,,26719833,65999,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
199,1863,2,1,,49648460,65999,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
200,1865,1,1,,26719833,65999,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
201,1865,1,1,,26749005,65999,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
202,1868,1,4,,26719833,65999,Inactive,4503895.0,2584.0,,Potency,qHTS Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
203,1875,2,1,,49648460,65999,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
204,1885,2,1,,49648460,65999,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
205,1899,1,3,,49648460,65999,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
206,1903,2,3,,26719833,65999,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
207,1903,2,3,,49648460,65999,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
208,1906,1,3,,49648460,65999,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
209,1910,1,2,,49648460,65999,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
210,1947,1,2,,49648460,65999,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
211,1948,1,1,,26749005,65999,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
212,1950,1,3,,49648460,65999,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
213,1956,1,1,,49648460,65999,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
214,1961,2,2,,26719833,65999,Inactive,33695107.0,9290.0,,EC50,Image-based HTS for Selective Agonists of GPR55,Confirmatory,,
215,1962,1,2,,49648460,65999,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
216,1974,1,2,,49648460,65999,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
217,1979,1,1,,49648460,65999,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
218,1984,1,3,,26719833,65999,Inactive,118026946.0,17979.0,,IC50,Fluorescence for the identification of compounds that decrease p/CIP protein stability,Confirmatory,,
219,1986,1,2,,26719833,65999,Inactive,45357394.0,,,IC50,uHTS fluorescence assay for the identification of Human Immunodeficiency Virus Fusion Inhibitors.,Confirmatory,,
220,1987,1,2,,49648460,65999,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
221,2006,3,2,,26719833,65999,Inactive,4507785.0,7329.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
222,2006,3,2,,26719833,65999,Inactive,13111961.0,10054.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
223,2006,3,2,,26719833,65999,Inactive,17390638.0,10055.0,,IC50,uHTS HTRF assay for identification of inhibitors of SUMOylation,Confirmatory,,
224,2012,3,2,,26719833,65999,Inactive,45219878.0,7458.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (eIF4H),Confirmatory,,
225,2013,2,2,,26719833,65999,Inactive,33695107.0,9290.0,,IC50,Image-Based HTS for Selective Antagonists for GPR55,Confirmatory,,
226,2014,3,2,,26719833,65999,Inactive,46367787.0,26986.0,,IC50,uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP),Confirmatory,,
227,2016,1,3,,49648460,65999,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
228,2023,1,3,,49648460,65999,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
229,2025,1,3,,49648460,65999,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
230,2029,1,3,,49648460,65999,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
231,2052,2,1,,49648460,65999,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
232,2057,1,2,,49648460,65999,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
233,2058,3,2,,26719833,65999,Inactive,33695097.0,2859.0,,IC50,Image-Based HTS for Selective Antagonists of GPR35,Confirmatory,,
234,2063,1,2,,85209733,65999,Active,,,,,Ligands of peptide (Class A) GPCRs,Other,,
235,2066,1,4,,49648460,65999,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
236,2071,2,2,,26719833,65999,Inactive,14719829.0,22861.0,,,Colorimetric  Assay for Inhibitors for NALP1,Screening,,
237,2073,2,3,,26719833,65999,Inactive,2625023.0,83589.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
238,2073,2,3,,26719833,65999,Inactive,4502523.0,774.0,,IC50,Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay,Confirmatory,,
239,2094,1,2,,49648460,65999,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
240,2094,1,2,,49648460,65999,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
241,2094,1,2,,49648460,65999,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
242,2097,1,2,,49648460,65999,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
243,2098,1,1,,49648460,65999,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
244,2099,1,1,,49648460,65999,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
245,2100,1,1,,26719833,65999,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen,Confirmatory,,
246,2101,1,1,,26719833,65999,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
247,2101,1,1,,26749005,65999,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
248,2107,1,1,,26719833,65999,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
249,2107,1,1,,26749005,65999,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
250,2112,1,1,,26719833,65999,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
251,2112,1,1,,26749005,65999,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
252,2129,1,2,,49648460,65999,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
253,2130,1,3,,49648460,65999,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
254,2147,1,1,,26719833,65999,Inconclusive,221046486.0,,11.2202,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
255,2147,1,1,,26749005,65999,Inconclusive,221046486.0,,25.1189,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
256,2156,2,2,,49648460,65999,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
257,2174,1,3,,49648460,65999,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
258,2177,1,3,,49648460,65999,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
259,2216,1,3,,49648460,65999,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
260,2221,1,2,,49648460,65999,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
261,2227,1,2,,49648460,65999,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
262,2234,1,2,,49648460,65999,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
263,2235,1,2,,49648460,65999,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
264,2237,1,2,,49648460,65999,Active,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
265,2239,1,2,,49648460,65999,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
266,2240,1,1,,85789678,65999,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
267,2241,1,1,,85789678,65999,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
268,2242,1,1,,26719833,65999,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease,Confirmatory,,
269,2247,1,2,,49648460,65999,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
270,2275,1,1,,85789678,65999,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
271,2280,2,3,,49648460,65999,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
272,2288,1,1,,26719833,65999,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/orActivators of miR-21,Confirmatory,,
273,2289,1,1,,26719833,65999,Inactive,,,,Potency,qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21,Confirmatory,,
274,2300,1,3,,49648460,65999,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
275,2313,1,1,,85789678,65999,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
276,2314,1,2,,26719833,65999,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
277,2314,1,2,,26719833,65999,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
278,2315,1,2,,26719833,65999,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
279,2315,1,2,,26719833,65999,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
280,2322,1,1,,85789678,65999,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
281,2330,1,1,,85789678,65999,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
282,2380,1,2,,49648460,65999,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
283,2391,1,1,,49648460,65999,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
284,2435,1,2,,49648460,65999,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
285,2445,1,2,,49648460,65999,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
286,2451,1,2,,26719833,65999,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
287,2451,1,2,,26749005,65999,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
288,2462,1,1,,49648460,65999,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
289,2462,1,1,,49648460,65999,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
290,2472,1,2,,26719833,65999,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
291,2472,1,2,,26749005,65999,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
292,2517,2,1,,26719833,65999,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
293,2517,2,1,,144205005,65999,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
294,2520,1,4,,49648460,65999,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
295,2521,1,3,,49648460,65999,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
296,2524,1,2,,49648460,65999,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
297,2528,1,2,,26719833,65999,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
298,2528,1,2,,26749005,65999,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
299,2540,1,2,,49648460,65999,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
300,2544,1,2,,49648460,65999,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
301,2546,1,1,,26719833,65999,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
302,2546,1,1,,26749005,65999,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
303,2549,1,1,,26719833,65999,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
304,2549,1,1,,26749005,65999,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
305,2550,1,3,,49648460,65999,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
306,2551,1,1,,26719833,65999,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
307,2551,1,1,,26749005,65999,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
308,2553,1,2,,49648460,65999,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
309,2557,1,3,,49648460,65999,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
310,2563,1,1,,49648460,65999,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
311,2599,1,2,,49648460,65999,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
312,2606,1,2,,49648460,65999,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
313,2629,1,1,,49648460,65999,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
314,2642,1,2,,49648460,65999,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
315,2648,1,2,,49648460,65999,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
316,2650,2,1,,49648460,65999,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
317,2661,1,1,,49648460,65999,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
318,2662,2,1,,26719833,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
319,2662,2,1,,26749005,65999,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
320,2675,1,1,,26719833,65999,Inactive,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
321,2676,1,2,,26719833,65999,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
322,2685,1,1,,26719833,65999,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
323,2690,1,2,,49648460,65999,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
324,2716,1,1,,49648460,65999,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
325,2717,1,2,,49648460,65999,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
326,2718,1,1,,49648460,65999,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
327,2732,1,1,,26719833,65999,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
328,2751,2,2,,49648460,65999,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
329,2796,1,4,,49648460,65999,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
330,2797,1,2,,49648460,65999,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
331,2805,2,2,,49648460,65999,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
332,2806,2,2,,49648460,65999,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
333,2825,1,2,,49648460,65999,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
334,23918,4,2,,103271997,65999,Unspecified,,,,,Renal clearance value was evaluated,Other,12773029.0,
335,26942,3,3,,103271997,65999,Unspecified,,,,,Absolute bioavailability of compound was determined,Other,12773029.0,
336,27037,3,3,,103271997,65999,Unspecified,,,,,Half life of compound was determined,Other,12773029.0,
337,27862,5,1,,103271997,65999,Unspecified,,,,,Total clearance value was evaluated,Other,12773029.0,
338,29138,3,3,,103271997,65999,Unspecified,,,,,Acid dissociation value was evaluated,Other,12773029.0,
339,37689,7,1,,103271997,65999,Active,,,0.003,IC50,Inhibition of specific binding of [125I]angiotensin-II to angiotensin 1 receptor in rat lung membrane preparation,Confirmatory,8258826.0,
340,39652,5,10,,103271997,65999,Unspecified,231519.0,185.0,,,"Inhibition against Angiotensin II receptor, type 1",Other,12773029.0,
341,39791,3,8,,103271997,65999,Unspecified,,,,,"Relative binding affinity of compound to Angiotensin II receptor, type 1 was determined",Other,12773029.0,
342,186525,3,4,,103271997,65999,Unspecified,,,,,Fall in mean arterial blood pressure (MABP) at 1 mg/kg po bid for 4 days after first treatment in conscious chronically-instrumented renovascular hypertensive rats,Other,8258826.0,
343,186689,3,4,,103271997,65999,Unspecified,,,,,Maximum fall in mean arterial blood pressure (MABP) at 1 mg/kg po bid after 4 days of treatment in conscious chronically-instrumented renovascular hypertensive rats,Other,8258826.0,
344,236277,5,2,,103271997,65999,Unspecified,,,,,Volume distribution was determined,Other,15974591.0,
345,237099,3,3,,103271997,65999,Unspecified,,,,,Time required for elimination of 50% of the compound,Other,15974591.0,
346,237841,3,3,,103271997,65999,Unspecified,,,,,Oral bioavailability,Other,15974591.0,
347,237981,3,3,,103271997,65999,Unspecified,,,,,Percentage modification of drug adsorbed after administration to human,Other,15974591.0,
348,239885,4,11,,103271997,65999,Unspecified,231519.0,185.0,,,pKa value against human Angiotensin II receptor type 1,Other,15974591.0,
349,243379,3,11,,103271997,65999,Unspecified,231519.0,185.0,,,Binding affinity for AT1 receptor,Other,15974591.0,
350,247113,3,11,,103271997,65999,Unspecified,231519.0,185.0,,,Maximal effect produced by the drug in human,Other,15974591.0,
351,410429,3,5,,103271997,65999,Unspecified,,,,,"Antihypertensive activity against angiopoietin 2-induced pressor response in conscious normotensive Beagle dog assessed as rate of change of mean systolic blood pressure at 2.13 mg/kg, po after 1 hr",Other,18976926.0,
352,410430,3,5,,103271997,65999,Unspecified,,,,,"Antihypertensive activity against angiopoietin 2-induced pressor response in conscious normotensive Beagle dog assessed as rate of change of mean diastolic blood pressure at 2.13 mg/kg, po after 1 hr",Other,18976926.0,
353,410605,3,5,,103271997,65999,Unspecified,,,,,"Antihypertensive activity against angiopoietin 2-induced pressor response in conscious normotensive Beagle dog assessed as rate of change of mean arterial blood pressure at 2.13 mg/kg, po after 1 hr",Other,18976926.0,
354,425652,7,2,,103271997,65999,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
355,425653,7,2,,103271997,65999,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
356,434955,1,2,,49648460,65999,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
357,434959,1,1,,85789678,65999,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
358,434962,1,2,,49648460,65999,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
359,434973,1,3,,49648460,65999,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
360,434989,1,1,,49648460,65999,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
361,435003,1,3,,49648460,65999,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
362,435022,2,2,,49648460,65999,Active,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
363,435030,1,2,,49648460,65999,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
364,435030,1,2,,49648460,65999,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
365,444050,7,1,,103271997,65999,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
366,444051,6,2,,103271997,65999,Unspecified,,,,,Total clearance in human,Other,20070106.0,
367,444052,6,2,,103271997,65999,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
368,444053,6,2,,103271997,65999,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
369,444054,6,1,,103271997,65999,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
370,444055,3,3,,103271997,65999,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
371,444056,3,3,,103271997,65999,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
372,444057,3,3,,103271997,65999,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
373,444058,6,2,,103271997,65999,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
374,444059,7,5,,103271997,65999,Active,113493.0,24180.0,0.00022999999999999998,Ki,Displacement of [125I]SI-Ang2 from AT1 receptor in Sprague-Dawley rat liver membrane,Confirmatory,20073471.0,
375,444060,3,9,,103271997,65999,Unspecified,13432234.0,5468.0,,,Agonist activity at human recombinant PPARgamma expressed in CV1 cells coexpressing GAL4 assessed as receptor transactivation at 10 uM by luciferase reporter gene assay relative to full agonist,Other,20073471.0,
376,449728,1,2,,49648460,65999,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
377,449746,1,2,,49648460,65999,Active,,,,,Single concentration confirmation of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
378,449762,1,2,,49648460,65999,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
379,449763,1,3,,49648460,65999,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
380,449768,1,1,,49648460,65999,Active,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
381,455986,3,5,,103271997,65999,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
382,459526,6,6,,103271997,65999,Active,13432234.0,5468.0,2.02,EC50,Agonist activity at human PPARgamma expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
383,459527,3,9,,103271997,65999,Unspecified,13432234.0,5468.0,,,Agonist activity at human PPARgamma expressed in african green monkey CV1 cells by Gal4 transactivation assay relative to rosiglitazone,Other,20079636.0,
384,459528,6,6,,103271997,65999,Unspecified,3041727.0,5465.0,10.0,EC50,Agonist activity at human PPARalpha expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
385,459530,5,7,,103271997,65999,Unspecified,417522.0,5467.0,10.0,EC50,Agonist activity at human PPARdelta expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
386,459531,8,5,,103271997,65999,Active,13432234.0,5468.0,12.2,IC50,"Displacement of radiolabeled ((5-{4-[Methyl-pyridin-2yl-amino)-ethoxy]-benzyl}-thiazolidine-2,4-dione) from human PPARgamma ligand binding domain expressed in Escherichia coli",Confirmatory,20079636.0,
387,459532,8,5,,103271997,65999,Unspecified,3041727.0,5465.0,10.0,IC50,Displacement of radiolabeled GW-2433 from human PPARalpha ligand binding domain expressed in Escherichia coli,Confirmatory,20079636.0,
388,459533,8,5,,103271997,65999,Unspecified,417522.0,5467.0,10.0,IC50,Displacement of radiolabeled GW-2433 from human PPARdelta ligand binding domain expressed in Escherichia coli,Confirmatory,20079636.0,
389,459534,6,6,,103271997,65999,Active,13432235.0,19016.0,4.06,EC50,Agonist activity at mouse PPARgamma expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
390,459535,3,9,,103271997,65999,Unspecified,13432235.0,19016.0,,,Agonist activity at mouse PPARgamma expressed in african green monkey CV1 cells by Gal4 transactivation assay relative to rosiglitazone,Other,20079636.0,
391,459536,6,6,,103271997,65999,Unspecified,1709728.0,19013.0,10.0,EC50,Agonist activity at mouse PPARalpha expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
392,459538,5,7,,103271997,65999,Unspecified,548577.0,19015.0,10.0,EC50,Agonist activity at mouse PPARdelta expressed in african green monkey CV1 cells by Gal4 transactivation assay,Confirmatory,20079636.0,
393,459552,6,2,,103271997,65999,Active,,,0.003,IC50,Inhibition of AT1 receptor,Confirmatory,20079636.0,
394,463079,1,2,,49648460,65999,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
395,463082,1,1,,49648460,65999,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
396,463104,1,2,,49648460,65999,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
397,463111,1,1,,49648460,65999,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
398,463141,1,2,,49648460,65999,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
399,463165,1,1,,49648460,65999,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
400,463190,1,2,,49648460,65999,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
401,463195,1,2,,49648460,65999,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
402,463210,1,2,,49648460,65999,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
403,463212,1,1,,49648460,65999,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
404,463254,1,1,,26719833,65999,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
405,476929,3,3,,103271997,65999,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
406,485270,1,1,,49648460,65999,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
407,485272,1,1,,49648460,65999,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
408,485273,2,1,,49648460,65999,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
409,485275,1,3,,49648460,65999,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
410,485281,1,1,,26719833,65999,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
411,485281,1,1,,26749005,65999,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
412,485290,1,1,,26719833,65999,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
413,485290,1,1,,26749005,65999,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
414,485294,1,1,,26719833,65999,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
415,485297,1,1,,26719833,65999,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
416,485298,1,1,,26719833,65999,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
417,485313,1,2,,26719833,65999,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
418,485314,1,1,,26719833,65999,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
419,485317,1,2,,49648460,65999,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
420,485341,1,1,,26719833,65999,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
421,485344,1,1,,26719833,65999,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
422,485346,1,1,,49648460,65999,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
423,485346,1,1,,49648460,65999,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
424,485347,1,2,,26719833,65999,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
425,485350,1,2,,92124871,65999,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
426,485353,2,1,,26719833,65999,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
427,485358,1,1,,26719833,65999,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
428,485364,1,1,,26719833,65999,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
429,485367,1,2,,26719833,65999,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
430,488837,1,1,,26719833,65999,Inconclusive,26667227.0,2139.0,28.1838,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
431,488847,1,3,,49648460,65999,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
432,488890,1,2,,49648460,65999,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
433,488922,1,2,,49648460,65999,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
434,488975,1,2,,49648460,65999,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
435,488977,1,2,,49648460,65999,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
436,489006,1,2,,49648460,65999,Inactive,,,80.0,IC50_Mean,Dose Response selectivity of uHTS chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation in Jurkat cells using a luminescence assay,Confirmatory,,
437,489021,1,2,,49648460,65999,Inactive,,,80.0,IC50_Mean,Dose response cytotoxicity of uHTS chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
438,489022,1,2,,49648460,65999,Inactive,,,80.0,IC50_Mean,Dose response counterscreen of uHTS chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation in a HEK-293T cell line using a luminescence assay,Confirmatory,,
439,489023,1,1,,49648460,65999,Inactive,,,72.5,IC50_Mean,Dose response confirmation of uHTS of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation in a 697B cell line using a luminescence assay,Confirmatory,,
440,489030,2,1,,49648460,65999,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
441,489031,2,1,,49648460,65999,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
442,492947,1,1,,26719833,65999,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
443,492961,1,1,,26749005,65999,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
444,493005,1,1,,49648460,65999,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
445,493011,1,1,,49648460,65999,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
446,493012,1,1,,49648460,65999,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
447,493014,1,1,,26719833,65999,Inconclusive,,,1.2589,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
448,493033,1,2,,92124871,65999,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
449,493036,1,2,,49648460,65999,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
450,493056,1,1,,26719833,65999,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
451,493084,1,1,,26719833,65999,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
452,493091,1,1,,49648460,65999,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
453,493098,1,1,,49648460,65999,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
454,493160,1,1,,49648460,65999,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
455,493187,1,2,,49648460,65999,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
456,499442,7,5,,103271997,65999,Active,13432234.0,5468.0,3.4,EC50,Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay,Confirmatory,20656494.0,
457,499443,2,10,,103271997,65999,Unspecified,13432234.0,5468.0,,,Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay relative to pioglitazone,Other,20656494.0,
458,499444,2,3,,103271997,65999,Unspecified,,,,,Induction of adipocyte differentiation in mouse ST-13 cells at 10 uM,Other,20656494.0,
459,504327,1,1,,26719833,65999,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
460,504327,1,1,,26749005,65999,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
461,504332,1,1,,26719833,65999,Active,168985070.0,,4.4668,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
462,504332,1,1,,26749005,65999,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
463,504333,1,1,,26719833,65999,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
464,504339,1,1,,49648460,65999,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
465,504406,1,1,,49648460,65999,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
466,504408,2,1,,49648460,65999,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
467,504444,1,1,,49648460,65999,Inconclusive,224028257.0,4780.0,23.1093,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
468,504462,1,1,,49648460,65999,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
469,504648,1,1,,49648460,65999,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
470,504651,1,1,,26719833,65999,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
471,504652,1,1,,26719833,65999,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
472,504660,1,1,,26719833,65999,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
473,504690,1,3,,49648460,65999,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
474,504720,1,1,,49648460,65999,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
475,504749,1,3,,26749005,65999,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,1.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,2.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,3.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,4.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,5.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,6.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,7.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504749,1,3,8.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
484,504749,1,3,9.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
485,504749,1,3,10.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
486,504749,1,3,11.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
487,504749,1,3,12.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
488,504749,1,3,13.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
489,504749,1,3,14.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
490,504749,1,3,15.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
491,504749,1,3,16.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
492,504749,1,3,17.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
493,504749,1,3,18.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
494,504749,1,3,19.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
495,504749,1,3,20.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
496,504749,1,3,21.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
497,504749,1,3,22.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
498,504749,1,3,23.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
499,504749,1,3,24.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
500,504749,1,3,25.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,26.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,27.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,28.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,29.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,30.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,31.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,32.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,33.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,34.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,35.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,36.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504749,1,3,37.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
513,504749,1,3,38.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
514,504749,1,3,39.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
515,504749,1,3,40.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
516,504749,1,3,41.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,42.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,43.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,44.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,45.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,46.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,47.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,48.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,49.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,50.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,51.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504749,1,3,52.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
528,504749,1,3,53.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
529,504749,1,3,54.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
530,504749,1,3,55.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
531,504749,1,3,56.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
532,504749,1,3,57.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
533,504749,1,3,58.0,26749005,65999,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
534,504749,1,3,59.0,26749005,65999,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
535,504749,1,3,60.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
536,504749,1,3,61.0,26749005,65999,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
537,504770,1,2,,92124871,65999,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
538,504810,1,2,,26719833,65999,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
539,504812,1,2,,26719833,65999,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
540,504832,1,1,,26749005,65999,Active,,,3.7933,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
541,504834,1,1,,26749005,65999,Active,,,1.5101,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
542,504842,1,1,,26719833,65999,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
543,504845,1,1,,49648460,65999,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
544,504847,1,1,,26749005,65999,Inconclusive,63054845.0,7421.0,28.1838,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
545,504847,1,1,,49648460,65999,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
546,504858,1,1,,49648460,65999,Active,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Retest of Primary Hits,Screening,,
547,504865,1,1,,26749005,65999,Active,118600387.0,7398.0,50.1187,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
548,504891,1,1,,49648460,65999,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
549,504894,1,1,,49648460,65999,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
550,504937,1,2,,49648460,65999,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
551,540209,4,3,,103271997,65999,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
552,540210,4,3,,103271997,65999,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
553,540211,2,5,,103271997,65999,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
554,540212,4,3,,103271997,65999,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
555,540213,4,3,,103271997,65999,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
556,540253,1,1,,49648460,65999,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
557,540253,1,1,,49648460,65999,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
558,540253,1,1,,49648460,65999,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
559,540263,1,1,,49648460,65999,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
560,540263,1,1,,49648460,65999,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
561,540267,1,1,,49648460,65999,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
562,540275,1,1,,26719833,65999,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
563,540277,1,1,,26719833,65999,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
564,540299,1,2,,92124871,65999,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
565,540303,1,1,,49648460,65999,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
566,540303,1,1,,49648460,65999,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
567,540303,1,1,,49648460,65999,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
568,540317,1,1,,49648460,65999,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
569,568924,2,3,,103271997,65999,Active,,,0.0037,Ki,Binding affinity to angiotensin AT1 receptor in rat lung membranes,Confirmatory,21071232.0,
570,576507,2,4,,103271997,65999,Active,,,1.6119999999999999,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay,Confirmatory,20547797.0,
571,588209,2,3,,103271997,65999,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
572,588210,2,4,,103271997,65999,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
573,588211,2,3,,103271997,65999,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
574,588212,2,3,,103271997,65999,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
575,588213,2,3,,103271997,65999,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
576,588342,1,1,,26719833,65999,Active,160794.0,,13.4591,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
577,588389,1,1,,49648460,65999,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists:Counterscreen of Primary Hits,Other,,
578,588413,1,2,,49648460,65999,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
579,588453,1,1,,49648460,65999,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
580,588456,1,1,,49648460,65999,Inactive,8659577.0,58819.0,79.4328,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
581,588473,1,1,,49648460,65999,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
582,588473,1,1,,49648460,65999,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
583,588475,1,2,,49648460,65999,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
584,588475,1,2,,49648460,65999,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
585,588478,1,2,,124799971,65999,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
586,588511,1,2,,49648460,65999,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
587,588519,1,2,,92124871,65999,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
588,588579,1,1,,26749005,65999,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
589,588579,1,1,,49648460,65999,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
590,588590,1,1,,49648460,65999,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
591,588591,1,1,,49648460,65999,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
592,588627,1,1,,49648460,65999,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
593,588675,1,1,,49648460,65999,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
594,588676,1,1,,49648460,65999,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
595,588795,1,1,,49648460,65999,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
596,588834,2,1,,144205005,65999,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
597,588855,1,1,,49648460,65999,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
598,588856,1,1,,49648460,65999,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
599,588963,1,10,,103271997,65999,Unspecified,27734563.0,28234.0,,,"Substrates of transporters of clinical importance in the absorption and disposition of drugs, OATP1B3",Other,20190787.0,
600,592681,1,4,,103271997,65999,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
601,602179,1,2,,49648460,65999,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
602,602233,1,1,,49648460,65999,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
603,602310,1,2,,49648460,65999,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
604,602313,1,1,,49648460,65999,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
605,602314,1,2,,92124871,65999,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
606,602332,1,1,,26749005,65999,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
607,602332,1,1,,49648460,65999,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
608,605745,1,4,,103271997,65999,Unspecified,,,,,"Antidiabetic activity in ZDF rat assessed as body weight gain at 100 mg/kg, po QD for 40 days (Rvb = 133+/-9 g)",Other,21557540.0,
609,605751,3,1,,103271997,65999,Unspecified,,,,,"Antidiabetic activity in ZDF rat assessed as adiponectin level at 100 mg/kg, po QD for 40 days (Rvb = 11.9+/-1.5 ug/ml)",Other,21557540.0,
610,605753,1,4,,103271997,65999,Active,,,,,"Antidiabetic activity in ZDF rat assessed as body weight gain at 100 mg/kg, po QD for 40 days measured on day 32 (Rvb = 133+/-9 g)",Other,21557540.0,
611,607037,5,5,,103271997,65999,Active,231519.0,185.0,0.00049,IC50,"Displacement of [125I]Tyr4-Sar1,Ile8-Angiotensin II from human Angiotensin 1 receptor after 60 mins by scintillation counting",Confirmatory,21557540.0,
612,607038,5,5,,103271997,65999,Active,13432234.0,5468.0,1.52,EC50,Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay,Confirmatory,21557540.0,
613,607039,1,9,,103271997,65999,Unspecified,13432234.0,5468.0,,,Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay relative to darglitazone,Other,21557540.0,
614,607114,1,4,,103271997,65999,Unspecified,,,,,"Antidiabetic activity in ZDF rat assessed as blood glucose level at 100 mg/kg, po QD for 40 days (Rvb = 771+/-60 mg/dL)",Other,21557540.0,
615,607120,1,4,,103271997,65999,Unspecified,,,,,"Antidiabetic activity in ZDF rat assessed as triglyceride level at 100 mg/kg, po QD for 40 days (Rvb = 618+/-52 mg/dL)",Other,21557540.0,
616,624030,1,2,,26749005,65999,Inconclusive,160794.0,,9.0743,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
617,624031,1,2,,26749005,65999,Inconclusive,,,36.1254,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
618,624032,1,2,,26749005,65999,Inconclusive,8393992.0,24660.0,28.6954,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
619,624044,1,2,,26749005,65999,Inconclusive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
620,624156,1,1,,85789678,65999,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
621,624170,1,1,,26749005,65999,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
622,624170,1,1,,49648460,65999,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
623,624171,1,1,,49648460,65999,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
624,624172,1,1,,26749005,65999,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
625,624172,1,1,,49648460,65999,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
626,624173,1,3,,26749005,65999,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
627,624173,1,3,,49648460,65999,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
628,624173,1,3,,124891851,65999,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
629,624178,1,1,,49648460,65999,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
630,624202,1,1,,49648460,65999,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
631,624246,1,1,,49648460,65999,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
632,624263,1,1,,49648460,65999,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
633,624263,1,1,,49648460,65999,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
634,624288,1,1,,49648460,65999,Inconclusive,52000961.0,2778.0,3.1623,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
635,624296,1,1,,26749005,65999,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
636,624296,1,1,,49648460,65999,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
637,624297,1,1,,26749005,65999,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
638,624297,1,1,,49648460,65999,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
639,624349,1,2,,92124871,65999,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
640,624349,1,2,,92308092,65999,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
641,624349,1,2,,92308546,65999,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
642,624349,1,2,,92309313,65999,Active,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
643,624414,1,1,,49648460,65999,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
644,624415,1,2,,49648460,65999,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
645,624417,1,1,,49648460,65999,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
646,624418,1,1,,49648460,65999,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
647,624463,1,1,,49648460,65999,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
648,624464,1,1,,49648460,65999,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
649,624465,1,1,,49648460,65999,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
650,624476,1,1,,137275807,65999,Inactive,,,,Potency,Cytotoxicity counterscreen for NFkB agonists and antagonists,Confirmatory,,
651,624478,1,1,,137275807,65999,Inactive,,,,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway.,Confirmatory,,
652,624479,1,1,,137275807,65999,Inactive,,,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway.,Confirmatory,,
653,625279,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
654,625280,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
655,625281,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
656,625282,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
657,625283,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
658,625284,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
659,625285,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
660,625286,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
661,625287,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
662,625288,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
663,625289,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
664,625290,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
665,625291,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
666,625292,1,3,,103271997,65999,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
667,644750,3,2,,103271997,65999,Active,,,0.001,IC50,Displacement of [125I]Sar1 Ile8-Ang 2 from angiotensin 2 AT1 receptor after 180 mins by gamma counting,Confirmatory,22309912.0,
668,644751,3,2,,103271997,65999,Active,,,0.00033,IC50,Displacement of [125I]Sar1 Ile8-Ang 2 from angiotensin 2 AT2 receptor after 180 mins by gamma counting,Confirmatory,22309912.0,
669,644754,3,2,,103271997,65999,Unspecified,,,,,Toxicity against Photobacterium phosphoreum T3 mutant assessed as inhibition of luminescence after 15 mins by microtox test,Other,22309912.0,
670,651550,1,1,,49648460,65999,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
671,651631,4,1,,144205005,65999,Inconclusive,269849759.0,7157.0,4.2163,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
672,651632,4,1,,144205005,65999,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
673,651633,4,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
674,651634,4,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
675,651635,1,3,,49648460,65999,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
676,651644,1,1,,49648460,65999,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
677,651645,1,1,,137275807,65999,Inactive,,,26.3506,Potency,Cell Proliferation Assay against the TMD8 Cell Line,Confirmatory,,
678,651646,1,1,,137275807,65999,Inactive,,,46.8587,Potency,Cell Proliferation Assay against the HBL1 Cell Line,Confirmatory,,
679,651696,1,1,,137275807,65999,Inactive,,,20.930999999999997,Potency,Cell Proliferation Assay against a hMSC Cell Line,Confirmatory,,
680,651712,1,1,,137275807,65999,Inactive,,,,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 16 hrs),Confirmatory,,
681,651713,1,1,,137275807,65999,Inactive,,,,Potency,Cell Proliferation Assay against the TMD8 Cell Line (Caspase readout at 8 hrs),Confirmatory,,
682,651724,1,1,,49648460,65999,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
683,651725,1,1,,49648460,65999,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
684,651768,1,2,,49648460,65999,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
685,651819,1,1,,49648460,65999,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
686,651820,1,1,,49648460,65999,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
687,651828,1,2,,92308546,65999,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
688,651828,1,2,,92309313,65999,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
689,651965,1,1,,49648460,65999,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
690,652025,1,1,,49648460,65999,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
691,652048,1,2,,49648460,65999,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
692,652048,1,2,,144205005,65999,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
693,652051,1,1,,49648460,65999,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
694,652051,1,1,,144205005,65999,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
695,652054,1,1,,49648460,65999,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
696,652104,1,1,,49648460,65999,Inconclusive,20140568.0,23435.0,0.3162,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
697,652105,1,1,,49648460,65999,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
698,652106,1,1,,49648460,65999,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
699,673037,4,1,,103271997,65999,Active,231519.0,185.0,0.001,IC50,Displacement of [125I]Sar1Ile8-Ang2 from angiotensin AT1 receptor after 180 mins by gamma counting,Confirmatory,22727371.0,
700,673041,2,2,,103271997,65999,Unspecified,,,,,Toxicity against Photobacterium phosphoreum expressing T3 mutation after 15 mins by Microtox assay,Other,22727371.0,
701,673042,4,1,,103271997,65999,Active,231519.0,185.0,0.15,IC50,Inhibition of angiotensin AT1 receptor,Confirmatory,22727371.0,
702,685500,2,2,,103271997,65999,Unspecified,,,10.0,IC50,HARVARD: Cytotoxicity in HepG2 cell line,Confirmatory,22586124.0,
703,685501,2,2,,103271997,65999,Active,,,0.025,IC50,HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells,Confirmatory,22586124.0,
704,685502,2,2,,103271997,65999,Unspecified,,,5.0,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection,Confirmatory,22586124.0,
705,685503,2,2,,103271997,65999,Unspecified,,,5.0,IC50,HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection,Confirmatory,22586124.0,
706,686947,2,2,,137275807,65999,Inactive,4885661.0,7525.0,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen,Confirmatory,23787099.0,
707,686950,1,1,,137275807,65999,Inactive,,,,Potency,qHTS for small molecule inhibitors of Yes1 kinase: Counter Assay,Other,,
708,686970,1,2,,49648460,65999,Inconclusive,49168486.0,3417.0,8.1995,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
709,686971,1,2,,49648460,65999,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
710,686978,1,1,,49648460,65999,Inconclusive,79154014.0,55775.0,23.1093,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
711,686978,1,1,,144205005,65999,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
712,686979,1,1,,49648460,65999,Inconclusive,79154014.0,55775.0,18.3564,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
713,686979,1,1,,144205005,65999,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
714,699539,1,7,,103271997,65999,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
715,699540,1,7,,103271997,65999,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
716,699541,1,7,,103271997,65999,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
717,717844,1,7,,103271997,65999,Unspecified,939108065.0,209176.0,,,Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control,Other,23122865.0,
718,720504,1,1,,49648460,65999,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
719,720516,2,1,,144205005,65999,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
720,720532,1,1,,144205005,65999,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
721,720533,1,1,,144205005,65999,Inconclusive,,,31.6228,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
722,720542,1,2,,49648460,65999,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
723,720551,1,2,,49648460,65999,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
724,720552,2,1,,144205005,65999,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
725,720553,1,2,,49648460,65999,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
726,720554,1,3,,92308546,65999,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
727,720579,2,1,,49648460,65999,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
728,720579,2,1,,144205005,65999,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
729,720580,1,1,,49648460,65999,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
730,720580,1,1,,144205005,65999,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
731,720634,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
732,720635,2,1,,144205005,65999,Inconclusive,,,0.8413,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
733,720637,2,1,,144205005,65999,Inconclusive,,,1.10053,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
734,720641,1,2,,92308092,65999,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
735,720641,1,2,,92308546,65999,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
736,720641,1,2,,92309313,65999,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
737,720674,2,2,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
738,720675,2,2,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
739,720678,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
740,720679,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
741,720680,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
742,720681,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
743,720682,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
744,720683,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
745,720684,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
746,720685,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
747,720686,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
748,720687,2,2,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
749,720691,4,1,,144205005,65999,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
750,720692,3,1,,144205005,65999,Inconclusive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
751,720693,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
752,720707,1,2,,49648460,65999,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
753,720708,1,2,,49648460,65999,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
754,720709,1,2,,49648460,65999,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
755,720711,1,2,,49648460,65999,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
756,720717,1,3,,92124871,65999,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
757,720717,1,3,,92308092,65999,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
758,720717,1,3,,92308546,65999,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
759,720717,1,3,,92309313,65999,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
760,720719,2,1,,144205005,65999,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
761,720725,2,1,,144205005,65999,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
762,721753,1,6,,103271997,65999,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
763,721754,2,5,,103271997,65999,Active,74731723.0,55244.0,17.9,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
764,728044,1,6,,103271997,65999,Unspecified,13432234.0,5468.0,,,Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay relative to darglitazone,Other,23265881.0,
765,728045,2,5,,103271997,65999,Active,13432234.0,5468.0,1.52,EC50,Partial agonist activity at human PPARgamma-LBD/Gal4 DNA binding domain by transactivation assay,Confirmatory,23265881.0,
766,728046,2,5,,103271997,65999,Active,231519.0,185.0,0.00049,IC50,"Displacement of [125I]Tyr4-Sar1,Ile8-Angiotensin II from human Angiotensin 1 receptor after",Confirmatory,23265881.0,
767,742786,2,2,,103271997,65999,Active,231519.0,185.0,,,Type-1 angiotensin II receptor antagonist,Other,16938288.0,
768,742786,2,2,,103271997,65999,Active,231519.0,185.0,,,Type-1 angiotensin II receptor antagonist,Other,18580862.0,
769,743012,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
770,743014,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
771,743015,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
772,743033,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
773,743035,2,1,,144205005,65999,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
774,743036,2,1,,144205005,65999,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
775,743040,3,1,,144205005,65999,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
776,743041,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
777,743042,3,1,,144205005,65999,Inactive,124375976.0,367.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
778,743053,2,1,,144205005,65999,Inconclusive,124375976.0,367.0,10.0846,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
779,743054,2,1,,144205005,65999,Inconclusive,124375976.0,367.0,8.7418,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
780,743063,2,1,,144205005,65999,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
781,743064,3,1,,144205005,65999,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
782,743065,3,1,,144205005,65999,Inconclusive,399498506.0,24831.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
783,743066,3,1,,144205005,65999,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
784,743067,2,1,,144205005,65999,Inconclusive,399498506.0,24831.0,28.1796,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
785,743069,2,1,,144205005,65999,Inconclusive,348019627.0,2099.0,9.5205,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
786,743074,2,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
787,743075,2,1,,144205005,65999,Inactive,348019627.0,2099.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
788,743077,2,1,,144205005,65999,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
789,743078,2,1,,144205005,65999,Inconclusive,348019627.0,2099.0,23.9145,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
790,743079,3,1,,144205005,65999,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
791,743080,3,1,,144205005,65999,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
792,743081,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
793,743083,3,1,,144205005,65999,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
794,743084,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
795,743085,3,1,,144205005,65999,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
796,743086,3,1,,144205005,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
797,743091,2,1,,144205005,65999,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
798,743094,3,1,,144205005,65999,Inconclusive,216409692.0,5468.0,0.674,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
799,743122,2,1,,144205005,65999,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
800,743139,2,1,,144205005,65999,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
801,743140,2,1,,144205005,65999,Active,216409692.0,5468.0,0.600704,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
802,743191,3,1,,170464873,65999,Inconclusive,216409692.0,5468.0,14.9589,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
803,743194,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
804,743199,2,1,,170464873,65999,Active,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
805,743202,4,1,,170464873,65999,Active,20149576.0,4780.0,26.6011,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
806,743203,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
807,743209,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
808,743210,4,1,,170464873,65999,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
809,743211,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
810,743212,3,1,,170464873,65999,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
811,743213,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
812,743215,3,1,,170464873,65999,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
813,743217,3,1,,170464873,65999,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
814,743218,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
815,743219,3,1,,170464873,65999,Active,20149576.0,4780.0,23.7083,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
816,743220,3,1,,170464873,65999,Inconclusive,325495553.0,9971.0,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
817,743221,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
818,743222,3,1,,170464873,65999,Inconclusive,216409708.0,7421.0,6.6819,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
819,743223,3,1,,170464873,65999,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
820,743224,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
821,743225,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
822,743226,2,1,,170464873,65999,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
823,743227,2,1,,170464873,65999,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
824,743228,3,1,,170464873,65999,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
825,743239,2,1,,170464873,65999,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
826,743240,2,1,,170464873,65999,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
827,743241,2,1,,170464873,65999,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
828,743242,2,1,,170464873,65999,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
829,743244,1,1,,137275807,65999,Inconclusive,,,46.8587,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
830,743244,1,1,,144205005,65999,Inconclusive,,,22.3872,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
831,743255,1,1,,49648460,65999,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
832,743266,1,2,,49648460,65999,Inactive,296080761.0,5745.0,35.4813,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
833,743268,1,1,,172080419,65999,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
834,743270,1,1,,172080419,65999,Active,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
835,743271,1,1,,172080419,65999,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
836,743272,1,1,,172080419,65999,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
837,743279,1,2,,49648460,65999,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
838,743281,1,1,,46386620,65999,Inactive,1778357.0,22341.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
839,743281,1,1,,46386620,65999,Inactive,219520294.0,8828.0,,,Microplate-based screening for small molecule inhibitors of Neuropilin-2/VEGF-C interactions,Screening,,
840,743322,2,1,,137275807,65999,Inactive,,,0.0019,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
841,743323,2,1,,137275807,65999,Inactive,,,0.9433,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
842,743324,2,1,,137275807,65999,Inactive,,,0.8407,Potency,qHTS profiling for inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
843,743344,1,1,,174007300,65999,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
844,743345,1,1,,174007300,65999,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
845,743346,1,1,,174007300,65999,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
846,743347,1,1,,174007300,65999,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
847,774875,2,3,,103271997,65999,Active,231519.0,185.0,0.001,IC50,Displacement of [125I]-Sar1Ile8-angiotensin 2 from angiotensin 2 AT1 receptor (unknown origin) after 180 mins by gamma counting analysis,Confirmatory,24007859.0,
848,977599,1,1,,103271997,65999,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
849,977600,1,1,,103271997,65999,Active,,,1.8620900000000002,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
850,977601,1,1,,103271997,65999,Active,,,1.03,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells,Confirmatory,23571415.0,
851,977602,1,2,,103271997,65999,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
852,977603,1,2,,103271997,65999,Active,,,1.2589299999999999,IC50,pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
853,977604,1,2,,103271997,65999,Active,,,0.96,Ki,Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells,Confirmatory,23571415.0,
854,1053194,1,1,,137275807,65999,Active,,,37.2212,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Independent  ATL cell lines,Confirmatory,,
855,1053195,1,1,,137275807,65999,Active,,,16.6261,Potency,Cell Proliferation Assay Versus the ED40515 IL2 Dependent  ATL cell lines,Confirmatory,,
856,1053270,4,2,,103271997,65999,Unspecified,113045.0,1636.0,,Ki,Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid after 60 mins by WST assay,Confirmatory,24088053.0,
857,1053271,1,4,,103271997,65999,Unspecified,113045.0,1636.0,,,Inhibition of ACE (unknown origin) assessed as 3-Hydroxybutyril-glycil-glycil-glycine conversion to 3-hydroxybutyric acid at 500 uM after 60 mins by WST assay relative to control,Other,24088053.0,
858,1070147,1,4,,103271997,65999,Unspecified,13432234.0,5468.0,,,Agonist activity at human PPARgamma expressed in CV-1 cells by reporter gene assay relative to rosiglitazone,Other,24462665.0,
859,1070148,2,3,,103271997,65999,Active,13432234.0,5468.0,2.02,EC50,Agonist activity at human PPARgamma expressed in CV-1 cells by reporter gene assay,Confirmatory,24462665.0,
860,1070149,2,3,,103271997,65999,Active,231519.0,185.0,0.002,IC50,Antagonist activity at human AT1 receptor expressed in CHO cells measured after overnight incubation by luciferase reporter gene assay,Confirmatory,24462665.0,
861,1094656,1,2,,103271997,65999,Active,,,,,Induction of adipocyte differentiation in Mus musculus (mouse) 3T3L1 cells at 1 to 5 uM,Other,,
862,1094657,2,3,,103271997,65999,Inconclusive,113493.0,24180.0,,Ki,Displacement of [125I]-SI-Ang-2 from AT1 receptor in Rattus norvegicus Sprague-Dawley (rat) liver membranes after 2 hr,Confirmatory,,
863,1094658,1,4,,103271997,65999,Unspecified,13432235.0,19016.0,,,Agonist activity at Mus musculus (mouse) PPARgamma LBD expressed in african green monkey CV-1 cells co-expressing GAL4 assessed as beta-galactosidase activity at 1 uM after 24 hr by luciferase assay relative to rosiglitazone,Other,,
864,1094660,1,4,,103271997,65999,Unspecified,13432234.0,5468.0,,,Agonist activity at Homo sapiens (human) PPARgamma LBD expressed in African green monkey CV-1 cells co-expressing GAL4 assessed as beta-galactosidase activity at 10 uM after 24 hr by luciferase reporter gene assay relative to rosiglitazone,Other,,
865,1094661,2,3,,103271997,65999,Active,113493.0,24180.0,0.00022999999999999998,Ki,Displacement of [125I]-SI-Ang-2 from AT1 receptor in Rattus norvegicus Sprague-Dawley (rat) liver membranes after 2 hr,Confirmatory,,
866,1094662,1,2,,103271997,65999,Active,,,,,Induction of adipocyte differentiation in Mus musculus (mouse) 3T3L1 cells at 1 to 5 uM,Other,,
867,1117298,1,2,,170464873,65999,Inactive,,,2.5119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
868,1117304,1,2,,170464873,65999,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
869,1117305,1,2,,170464873,65999,Inactive,,,2.8184,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
870,1117310,1,1,,170464873,65999,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
871,1117312,1,1,,170464873,65999,Inactive,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
872,1117314,1,1,,170464873,65999,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
873,1117319,1,2,,26719833,65999,Inactive,9629361.0,155459.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
874,1117319,1,2,,26719833,65999,Inactive,13399304.0,60489.0,,Average IC50,High Throughput Screen to Identify Inhibitors Targeting HIV-1 Vif-dependent Degradation of Human APOBEC3G:#A time-resolved fluorescence resonance energy transfer (TR-FRET) assay for HIV-1 Vif-APOBEC3G interaction,Confirmatory,,
875,1117326,1,1,,170464873,65999,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
876,1117329,1,1,,170464873,65999,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
877,1117336,1,1,,170464873,65999,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
878,1117340,1,1,,170464873,65999,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
879,1117341,1,1,,170464873,65999,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
880,1117342,1,1,,170464873,65999,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
881,1117343,1,1,,170464873,65999,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
882,1117346,1,1,,170464873,65999,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
883,1129361,1,1,,103271997,65999,Unspecified,,,,,Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis,Other,24601604.0,
884,1159387,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
885,1159389,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
886,1159390,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
887,1159391,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole dog plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
888,1159394,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
889,1159396,1,2,,103271997,65999,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
890,1159509,1,1,,170464873,65999,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
891,1159510,3,1,,137275807,65999,Active,,,26.3506,Potency,Immunotoxin (HA22) sensitization/mitigation study. Vehicle arm (PBS),Confirmatory,,
892,1159511,3,1,,137275807,65999,Inactive,,,,Potency,Immunotoxin (SS1P) sensitization/mitigation study - treatment arm,Confirmatory,,
893,1159512,3,1,,137275807,65999,Active,,,16.6261,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (low dose),Confirmatory,,
894,1159513,3,1,,137275807,65999,Inactive,,,,Potency,Immunotoxin (SS1P) sensitization/mitigation study. Vehicle arm (DMEM),Confirmatory,,
895,1159515,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
896,1159516,1,1,,170464873,65999,Inconclusive,119611100.0,22926.0,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
897,1159517,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
898,1159518,1,1,,170464873,65999,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
899,1159519,1,1,,170464873,65999,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
900,1159520,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
901,1159521,1,1,,170464873,65999,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
902,1159523,1,1,,170464873,65999,Inconclusive,15928672.0,19885.0,6.3086199999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
903,1159524,1,1,,49648460,65999,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
904,1159524,1,1,,144205005,65999,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
905,1159525,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
906,1159526,1,1,,170464873,65999,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
907,1159527,1,1,,170464873,65999,Inconclusive,325495497.0,6256.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
908,1159528,1,1,,170464873,65999,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
909,1159529,1,1,,170464873,65999,Inconclusive,,,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
910,1159530,2,1,,137275807,65999,Inconclusive,,,0.0042,Potency,Immunotoxin (HA22) sensitization/mitigation study - treatment arm (High Dose),Confirmatory,,
911,1159531,1,1,,170464873,65999,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
912,1159550,3,1,,252402662,65999,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
913,1159551,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
914,1159552,1,1,,170464873,65999,Inactive,325495463.0,5914.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
915,1159553,2,1,,170464873,65999,Inactive,325495463.0,5914.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
916,1159555,1,1,,170464873,65999,Inconclusive,325495463.0,5914.0,12.3481,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
917,1159580,2,1,,268735070,65999,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
918,1159607,2,1,,312310150,65999,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
919,1159614,1,2,,170464873,65999,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
920,1159620,1,1,,103271997,65999,Active,,,,,Summary of drug indications.,Other,,
921,1193492,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 4 hrs by 96 well plate method",Other,25740159.0,
922,1193493,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in PBS at pH 7.4 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
923,1193494,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated gastric fluid at pH 1.2 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
924,1193495,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in simulated intestinal fluid at pH 6.8 at RT after 4 hrs by 96 well plate method",Other,25740159.0,
925,1193496,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound in water at RT after 24 hrs by shake-flask method",Other,25740159.0,
926,1193497,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound PBS at pH 7.4 at RT after 24 hrs by shake-flask method",Other,25740159.0,
927,1193498,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated gastric fluid at pH 1.2 at RT after 24 hrs by shake-flask method",Other,25740159.0,
928,1193499,1,1,,103271997,65999,Unspecified,,,,,"Thermodynamic equilibrium solubility, log S of the compound simulated intestinal fluid at pH 6.8 at RT after 24 hrs by shake-flask method",Other,25740159.0,
929,1203549,1,2,,103271997,65999,Unspecified,116242495.0,2741.0,,,Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 1 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control,Other,25790278.0,
930,1203550,1,2,,103271997,65999,Active,116242495.0,2741.0,3.2,EC50,Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents after 1 to 4 days by two-electrode voltage clamp assay,Confirmatory,25790278.0,
931,1203551,1,2,,103271997,65999,Unspecified,116242495.0,2741.0,,,Potentiation of human GlyR-alpha1 expressed in Xenopus laevis oocytes assessed as induction of glycine-activated currents at 10 uM after 1 to 4 days by two-electrode voltage clamp assay relative to control,Other,25790278.0,
932,1210068,1,2,,103271997,65999,Active,21264413.0,1573.0,0.1,Ki,Non-competitive inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method and Dixon plot,Confirmatory,23033255.0,
933,1210069,1,2,,103271997,65999,Active,21264413.0,1573.0,0.42,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
934,1210070,1,2,,103271997,65999,Unspecified,84028191.0,1565.0,50.0,IC50,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,Confirmatory,23033255.0,
935,1210071,1,2,,103271997,65999,Unspecified,116241312.0,1576.0,50.0,IC50,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,Confirmatory,23033255.0,
936,1210072,1,2,,103271997,65999,Active,6686268.0,1559.0,4.78,IC50,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,Confirmatory,23033255.0,
937,1210073,1,2,,103271997,65999,Unspecified,60416369.0,1557.0,50.0,IC50,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,Confirmatory,23033255.0,
938,1210074,1,2,,103271997,65999,Unspecified,117144.0,1544.0,50.0,IC50,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,Confirmatory,23033255.0,
939,1210075,1,2,,103271997,65999,Unspecified,21264413.0,1573.0,,,Ratio of IC50 for human recombinant CYP2J2 in absence of 1 mM NADPH to IC50 for human recombinant CYP2J2 in absence of 1 mM NADPH,Other,23033255.0,
940,1210079,1,2,,103271997,65999,Unspecified,,,,,Metabolic stability in human liver microsomes at 1 uM after 30 mins by LC-MS/MS method,Other,23033255.0,
941,1210080,1,2,,103271997,65999,Active,21264413.0,1573.0,0.54,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation reduction in astemizole O-demethylation after 30 mins by LC-MS/MS method in absence of 1 mM NADPH,Confirmatory,23033255.0,
942,1210081,1,2,,103271997,65999,Active,21264413.0,1573.0,0.54,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation after 30 mins by LC-MS/MS method in presence of 1 mM NADPH,Confirmatory,23033255.0,
943,1210082,1,2,,103271997,65999,Active,21264413.0,1573.0,0.19,Ki,Mixed type inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
944,1210084,1,1,,103271997,65999,Unspecified,,,,,"Selectivity index, ratio of IC50 for CYP21A2 in human liver microsomes to IC50 for human recombinant CYP2J2",Other,23033255.0,
945,1210085,1,1,,103271997,65999,Unspecified,,,,,"Selectivity index, ratio of IC50 for CYP3A4 in human liver microsomes to IC50 for human recombinant CYP2J2",Other,23033255.0,
946,1210086,1,1,,103271997,65999,Unspecified,,,,,"Selectivity index, ratio of IC50 for CYP2D6 in human liver microsomes to IC50 for human recombinant CYP2J2",Other,23033255.0,
947,1210087,1,1,,103271997,65999,Unspecified,,,,,"Selectivity index, ratio of IC50 for CYP2C9 in human liver microsomes to IC50 for human recombinant CYP2J2",Other,23033255.0,
948,1210088,1,1,,103271997,65999,Unspecified,,,,,"Selectivity index, ratio of IC50 for CYP2C19 in human liver microsomes to IC50 for human recombinant CYP2J2",Other,23033255.0,
949,1211171,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human kidney microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
950,1211178,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human intestinal microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
951,1211185,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM,Other,22275465.0,
952,1211192,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM,Other,22275465.0,
953,1211199,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM,Other,22275465.0,
954,1211206,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human liver microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
955,1211210,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
956,1211213,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
957,1211215,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
958,1211218,1,2,,103271997,65999,Unspecified,,,,,Ratio of unbound intrinsic glucuronidation clearance in human liver microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human liver microsomes in absence of bovine serum albumin,Other,22275465.0,
959,1211220,1,1,,103271997,65999,Unspecified,,,,,Ratio of unbound intrinsic glucuronidation clearance in human kidney microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human kidney microsomes in absence of bovine serum albumin,Other,22275465.0,
960,1211222,1,1,,103271997,65999,Unspecified,,,,,Ratio of unbound intrinsic glucuronidation clearance in human intestinal microsomes in presence of 1% bovine serum albumin to unbound intrinsic glucuronidation clearance in human intestinal microsomes in absence of bovine serum albumin,Other,22275465.0,
961,1211230,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human liver microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
962,1211237,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound glucuronidation in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
963,1211239,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound glucuronidation in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
964,1211241,1,1,,103271997,65999,Unspecified,,,,,Fraction unbound glucuronidation in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis,Other,22275465.0,
965,1211243,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound glucuronidation in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
966,1211245,1,2,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
967,1211248,1,2,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 1% bovine serum albumin,Other,22275465.0,
968,1211251,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase,Other,22275465.0,
969,1211256,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human intestinal microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
970,1211263,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
971,1211270,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
972,1211277,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Ratio of UGT1A3-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A3-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM in presence of 1% bovine serum albumin,Other,22275465.0,
973,1211278,1,1,,103271997,65999,Unspecified,,,,,Clearance in iv dosed human,Other,22275465.0,
974,1211279,1,1,,103271997,65999,Unspecified,,,,,Renal clearance in human,Other,22275465.0,
975,1211280,1,1,,103271997,65999,Unspecified,,,,,Fraction unbound glucuronidation in human plasma,Other,22275465.0,
976,1211281,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level blood to plasma in human,Other,22275465.0,
977,1211282,1,2,,103271997,65999,Unspecified,,,,,Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase,Other,22275465.0,
978,1211283,1,2,,103271997,65999,Unspecified,,,,,Fraction metabolized glucuronidation in human liver microsomes in presence of UDP-glucuronosyltransferase and bovine serum albumin,Other,22275465.0,
979,1211284,1,2,,103271997,65999,Unspecified,,,,,Glucuronidation clearance in human liver microsomes,Other,22275465.0,
980,1211285,1,2,,103271997,65999,Unspecified,,,,,Glucuronidation clearance in human liver microsomes in presence of bovine serum albumin,Other,22275465.0,
981,1211290,1,2,,103271997,65999,Unspecified,549152.0,54659.0,,,Drug metabolism in human kidney microsomes assessed as UGT1A3-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin,Other,22275465.0,
982,1214042,1,2,,103271997,65999,Unspecified,,,,,AUC in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
983,1214043,1,2,,103271997,65999,Unspecified,,,,,Cmax in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
984,1214044,1,2,,103271997,65999,Unspecified,,,,,Half life in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
985,1214045,1,1,,103271997,65999,Unspecified,,,,,Tmax in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
986,1214046,1,2,,103271997,65999,Unspecified,,,,,Clearance in human plasma expressing CYP2C8*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
987,1214047,1,2,,103271997,65999,Unspecified,,,,,AUC in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
988,1214048,1,2,,103271997,65999,Unspecified,,,,,Cmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
989,1214049,1,2,,103271997,65999,Unspecified,,,,,Half life in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
990,1214050,1,1,,103271997,65999,Unspecified,,,,,Tmax in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
991,1214051,1,2,,103271997,65999,Unspecified,,,,,Clearance in human plasma expressing CYP2C8*2 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
992,1214052,1,2,,103271997,65999,Unspecified,,,,,AUC in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
993,1214053,1,2,,103271997,65999,Unspecified,,,,,Cmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
994,1214054,1,2,,103271997,65999,Unspecified,,,,,Half life in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
995,1214055,1,1,,103271997,65999,Unspecified,,,,,Tmax in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
996,1214056,1,2,,103271997,65999,Unspecified,,,,,Clearance in human plasma expressing CYP2C8*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
997,1214057,1,2,,103271997,65999,Unspecified,,,,,AUC in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
998,1214058,1,2,,103271997,65999,Unspecified,,,,,Cmax in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
999,1214059,1,2,,103271997,65999,Unspecified,,,,,Half life in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1000,1214060,1,1,,103271997,65999,Unspecified,,,,,Tmax in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1001,1214061,1,2,,103271997,65999,Unspecified,,,,,Clearance in human plasma expressing CYP2C9*1/*1 polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1002,1214062,1,2,,103271997,65999,Unspecified,,,,,AUC in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1003,1214063,1,2,,103271997,65999,Unspecified,,,,,Cmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1004,1214064,1,2,,103271997,65999,Unspecified,,,,,Half life in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1005,1214065,1,1,,103271997,65999,Unspecified,,,,,Tmax in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1006,1214076,1,2,,103271997,65999,Unspecified,,,,,Clearance in human plasma expressing CYP2C9*3 allele carrier polymorphism at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1007,1214168,1,2,,103271997,65999,Unspecified,,,,,AUC in men plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1008,1214169,1,2,,103271997,65999,Unspecified,,,,,AUC in women plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1009,1214170,1,2,,103271997,65999,Unspecified,,,,,Cmax in men plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1010,1214171,1,2,,103271997,65999,Unspecified,,,,,Cmax in women plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1011,1214172,1,2,,103271997,65999,Unspecified,,,,,Half life in men plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1012,1214173,1,2,,103271997,65999,Unspecified,,,,,Half life in women plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1013,1214174,1,1,,103271997,65999,Unspecified,,,,,Tmax in men plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1014,1214175,1,1,,103271997,65999,Unspecified,,,,,Tmax in women plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1015,1214176,1,2,,103271997,65999,Unspecified,,,,,Clearance in men plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1016,1214177,1,2,,103271997,65999,Unspecified,,,,,Clearance in women plasma at 80 mg by LC/MS/MS analysis,Other,23118328.0,
1017,1216814,1,2,,103271997,65999,Unspecified,6686268.0,1559.0,,,Metabolic activation assessed as CYP2C9 activation-induced cytotoxicity in human HepG2 cells transfected with human AdCYP2C9 at MOI 10 for 2 days in presence of siNrf2 at 25 to 100 uM after 24 hrs by WST-8 assay,Other,21321060.0,
1018,1220237,1,1,,103271997,65999,Unspecified,,,,,Unbound fraction during UGT-mediated glucuronidation in human intestinal microsomes,Other,22685216.0,
1019,1220238,1,1,,103271997,65999,Unspecified,,,,,Intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance,Other,22685216.0,
1020,1220239,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic clearance in human intestinal microsomes assessed UGT-mediated glucuronidation clearance,Other,22685216.0,
1021,1220240,1,1,,103271997,65999,Inconclusive,,,,,Unbound fraction during CYP4500-mediated metabolism in human intestinal microsomes,Other,22685216.0,
1022,1220241,1,1,,103271997,65999,Unspecified,,,,,Intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance,Other,22685216.0,
1023,1220242,1,1,,103271997,65999,Unspecified,,,,,Unbound intrinsic clearance in human intestinal microsomes assessed CYP450-mediated glucuronidation clearance,Other,22685216.0,
1024,1220255,1,1,,103271997,65999,Unspecified,,,,,Apparent permeability by PAMPA method,Other,22685216.0,
1025,1220256,1,1,,103271997,65999,Unspecified,,,,,Total clearance in human,Other,22685216.0,
1026,1220257,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,22685216.0,
1027,1220258,1,1,,103271997,65999,Unspecified,,,,,Renal clearance in human,Other,22685216.0,
1028,1220259,1,1,,103271997,65999,Unspecified,,,,,Oral absorption in human,Other,22685216.0,
1029,1220554,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in Wistar Han rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1030,1220555,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in Sprague-Dawley rat brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1031,1220556,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in CD-1 mouse brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1032,1220557,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in Hartley guinea pig brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1033,1220558,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in Beagle dog brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1034,1220559,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in cynomolgus monkey brain homogenates at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1035,1220560,1,1,,103271997,65999,Unspecified,,,,,Fraction unbound in human occipital cortex at 1 uM after 6 hrs by equilibrium dialysis method,Other,21474681.0,
1036,1220784,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in mouse plasma by ultracentrifugation method,Other,21282406.0,
1037,1220785,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in rat plasma by ultracentrifugation method,Other,21282406.0,
1038,1220786,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in monkey plasma by ultracentrifugation method,Other,21282406.0,
1039,1220787,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in dog plasma by ultracentrifugation method,Other,21282406.0,
1040,1220788,1,2,,103271997,65999,Unspecified,,,,,Fraction unbound in human plasma by ultracentrifugation method,Other,21282406.0,
1041,1220789,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in mouse,Other,21282406.0,
1042,1220790,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in rat,Other,21282406.0,
1043,1220791,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in monkey,Other,21282406.0,
1044,1220792,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in dog,Other,21282406.0,
1045,1220793,1,2,,103271997,65999,Unspecified,,,,,Ratio of drug level in blood to plasma in human,Other,21282406.0,
1046,1220794,1,1,,103271997,65999,Unspecified,,,,,Plasma clearance in human,Other,21282406.0,
1047,1220795,1,1,,103271997,65999,Unspecified,,,,,Plasma clearance in po dosed human,Other,21282406.0,
1048,1220796,1,1,,103271997,65999,Unspecified,,,,,"Drug metabolism in bile duct-cannulated rat assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1049,1220797,1,1,,103271997,65999,Unspecified,,,,,Volume of distribution at steady state in human,Other,21282406.0,
1050,1220798,1,1,,103271997,65999,Unspecified,,,,,Half life in human,Other,21282406.0,
1051,1220799,1,1,,103271997,65999,Unspecified,,,,,"Drug metabolism in gallbladder-cannulated mouse assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1052,1220800,1,1,,103271997,65999,Unspecified,,,,,"Drug metabolism in bile duct-cannulated monkey assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1053,1220801,1,1,,103271997,65999,Unspecified,,,,,"Drug metabolism in bile duct-cannulated dog assessed as glucuronide concentration in bile and urine at 0.2 mg/kg, iv up to 24 hrs by LC/MS/MS analysis",Other,21282406.0,
1054,1224824,1,1,,174007300,65999,Inactive,,,4.6859,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1055,1224825,1,1,,174007300,65999,Inactive,,,0.0093,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1056,1224834,3,1,,170464873,65999,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1057,1224835,1,1,,170464873,65999,Active,160794.0,,13.8029,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1058,1224836,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1059,1224837,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1060,1224838,1,1,,170464873,65999,Inactive,66775687.0,9970.0,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1061,1224839,1,1,,170464873,65999,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1062,1224840,3,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1063,1224841,3,1,,170464873,65999,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1064,1224842,3,1,,170464873,65999,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1065,1224843,1,1,,170464873,65999,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1066,1224844,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1067,1224845,1,1,,170464873,65999,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1068,1224846,1,1,,170464873,65999,Inconclusive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1069,1224847,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1070,1224848,3,1,,170464873,65999,Inconclusive,325495545.0,2101.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1071,1224849,3,1,,170464873,65999,Inactive,325495545.0,2101.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1072,1224857,2,1,,170464873,65999,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1073,1224857,2,1,,174007300,65999,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1074,1224859,2,1,,170464873,65999,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1075,1224859,2,1,,174007300,65999,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1076,1224863,1,1,,176484478,65999,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1077,1224863,1,1,,176484812,65999,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1078,1224863,1,1,,316919031,65999,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1079,1224867,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1080,1224868,1,1,,170464873,65999,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1081,1224869,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1082,1224870,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1083,1224871,1,1,,170464873,65999,Inactive,,,0.3378,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1084,1224872,1,1,,170464873,65999,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1085,1224873,1,1,,170464873,65999,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1086,1224874,1,1,,170464873,65999,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1087,1224875,1,1,,170464873,65999,Inactive,,,0.5354,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1088,1224876,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1089,1224877,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1090,1224878,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1091,1224879,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1092,1224880,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1093,1224881,1,1,,170464873,65999,Inactive,,,0.5354,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1094,1224882,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1095,1224883,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1096,1224884,1,1,,170464873,65999,Inactive,,,0.379,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1097,1224885,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1098,1224886,1,1,,170464873,65999,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1099,1224887,1,1,,170464873,65999,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1100,1224888,1,1,,170464873,65999,Inactive,,,0.5354,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1101,1224889,1,1,,170464873,65999,Inconclusive,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1102,1224890,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1103,1224892,1,1,,170464873,65999,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1104,1224893,1,1,,170464873,65999,Inconclusive,66775687.0,9970.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1105,1224894,1,1,,170464873,65999,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1106,1224895,1,1,,170464873,65999,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1107,1224896,1,1,,170464873,65999,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1108,1224905,2,1,,92309313,65999,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1109,1224905,2,1,,92309313,65999,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1110,1231381,1,1,,103271997,65999,Active,13432234.0,5468.0,4.5,EC50,Activity at full length human PPARgamma transfected in CV1 cells assessed as transactivation activity after 24 hrs by PPRE-TK- luciferase reporter gene assay,Confirmatory,25734377.0,
1111,1231382,1,1,,103271997,65999,Unspecified,13432234.0,5468.0,,,Activity at full length human PPARgamma transfected in CV1 cells assessed as transactivation activity after 24 hrs by PPRE-TK- luciferase reporter gene assay relative to rosiglitazone,Other,25734377.0,
1112,1259241,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1113,1259242,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1114,1259243,1,1,,170464873,65999,Inactive,124375976.0,367.0,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1115,1259244,1,1,,170464873,65999,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1116,1259247,1,1,,170464873,65999,Inconclusive,124375976.0,367.0,29.8493,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1117,1259248,1,1,,170464873,65999,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1118,1259251,1,1,,46386620,65999,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of Unc-51 Like Autophagy Activating Kinase 1 (ULK1).,Screening,,
1119,1259252,1,1,,174007300,65999,Inconclusive,169655958.0,,33.1734,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1120,1259253,1,1,,174007300,65999,Inconclusive,169655958.0,,33.1734,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1121,1259255,1,1,,174007300,65999,Inconclusive,169655958.0,,33.1734,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1122,1259256,1,1,,174007300,65999,Inconclusive,169655958.0,,37.2212,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1123,1259310,1,1,,46386620,65999,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1124,1259310,1,1,,333473258,65999,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1125,1259310,1,1,,333473397,65999,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1126,1259313,1,1,,49648460,65999,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
1127,1259325,1,2,,336954405,65999,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1128,1259344,1,1,,144205005,65999,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1129,1259355,1,1,,144205005,65999,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1130,1259356,1,1,,144205005,65999,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1131,1259357,1,1,,137275807,65999,Inactive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A2780, Spheroid)",Confirmatory,,
1132,1259358,1,1,,137275807,65999,Inactive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Adherent)",Confirmatory,,
1133,1259359,1,1,,137275807,65999,Inconclusive,,,29.5659,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Spheroid)",Confirmatory,,
1134,1259360,1,1,,137275807,65999,Inactive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (SN12C, Spheroid)",Confirmatory,,
1135,1259361,1,1,,137275807,65999,Inactive,,,,Activity at 9.921 uM,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (A278, Adherent)",Confirmatory,,
1136,1259362,1,1,,137275807,65999,Inactive,,,,Potency,"Identifying Small Molecule Inhibitors of Pancreatic Cancer Stem Cells (Panc1, Adherent)",Confirmatory,,
1137,1259364,1,1,,170464873,65999,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1138,1259365,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1139,1259366,1,1,,170464873,65999,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1140,1259367,1,1,,170464873,65999,Inconclusive,,,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1141,1259368,1,1,,170464873,65999,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1142,1259369,1,1,,170464873,65999,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1143,1259377,1,1,,170464873,65999,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1144,1259378,1,1,,170464873,65999,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1145,1259379,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1146,1259380,1,1,,170464873,65999,Inconclusive,,,7.4978,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1147,1259381,1,1,,170464873,65999,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1148,1259382,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1149,1259383,1,1,,170464873,65999,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1150,1259384,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1151,1259385,1,1,,170464873,65999,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1152,1259386,1,1,,170464873,65999,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1153,1259387,1,1,,170464873,65999,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1154,1259388,1,1,,170464873,65999,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1155,1259389,1,1,,124637350,65999,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1156,1259390,1,1,,170464873,65999,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1157,1259391,1,1,,170464873,65999,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1158,1259392,1,1,,170464873,65999,Inconclusive,109731339.0,2737.0,11.8832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1159,1259393,1,1,,170464873,65999,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1160,1259394,1,1,,170464873,65999,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1161,1259395,1,1,,170464873,65999,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1162,1259396,1,1,,170464873,65999,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1163,1259400,1,1,,170464873,65999,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1164,1259401,1,1,,170464873,65999,Inconclusive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1165,1259402,1,1,,170464873,65999,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1166,1259403,1,1,,170464873,65999,Active,325495545.0,2101.0,23.7101,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1167,1259404,1,1,,170464873,65999,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1168,1259406,1,1,,363920186,65999,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
1169,1259406,1,1,1.0,363920186,65999,Inactive,26638650.0,3778.0,-0.0744517,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
1170,1259406,1,1,2.0,363920186,65999,Inactive,4758626.0,3779.0,0.00162988,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1171,1259406,1,1,3.0,363920186,65999,Inactive,5031823.0,10242.0,0.0250067,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1172,1259406,1,1,4.0,363920186,65999,Inactive,26051275.0,27345.0,-0.0009756519999999999,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1173,1259406,1,1,5.0,363920186,65999,Inactive,160410009.0,389816.0,0.05404590000000001,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1174,1259406,1,1,6.0,363920186,65999,Inactive,26638650.0,3778.0,-0.0814455,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
1175,1259406,1,1,7.0,363920186,65999,Inactive,4758626.0,3779.0,-0.025587799999999997,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
1176,1259406,1,1,8.0,363920186,65999,Inactive,5031823.0,10242.0,-0.00129177,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
1177,1259406,1,1,9.0,363920186,65999,Inactive,26051275.0,27345.0,0.0329731,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
1178,1259406,1,1,10.0,363920186,65999,Inactive,5031823.0,10242.0,0.016799400000000003,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
1179,1259413,1,2,,46386620,65999,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
1180,1259416,1,2,,340081541,65999,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1181,1259421,1,1,,340081541,65999,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1182,1259423,1,2,,354938460,65999,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1183,1259423,1,2,,354956423,65999,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1184,1259423,1,2,,355027766,65999,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
